PubMedCentralPubMedCrossRef 3 Whitesell L, Lindquist SL: HSP90 a

PubMedCentralPubMedCrossRef 3. Whitesell L, Lindquist SL: HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005, 5:761–772.PubMedCrossRef 4. Cheng Q, Chang JT, Geradts J, Neckers LM, Haystead T, Spector NL, Lyerly HK: Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human DMXAA solubility dmso epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res 2012, 14:R62.PubMedCentralPubMedCrossRef

5. Whitesell L, Lin NU: HSP90 as a platform for the assembly of more effective cancer chemotherapy. Biochim Biophys Acta 1823, 2012:756–766. 6. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM: Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994, 91:8324–8328.PubMedCrossRef

7. Taldone T, Gozman A, Maharaj R, Chiosis G: Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 2008, 8:370–374.PubMedCentralPubMedCrossRef 8. Jhaveri K, Taldone T, Modi S, Chiosis G: Advances in the clinical Selleck MRT67307 development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 1823, 2012:742–755. 9. Travers J, Sharp S, Workman P: HSP90 inhibition: two-pronged exploitation of cancer dependencies. Drug Discov Today 2012, 17:242–252.PubMedCrossRef 10. Taipale M, Jarosz DF, Lindquist S: HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010, 11:515–528.PubMedCrossRef 11. Mellman I, Coukos G, Dranoff G: Cancer immunotherapy comes of age. Nature 2011, 480:480–489.PubMedCrossRef Carnitine palmitoyltransferase II 12. Steinman RM, Banchereau J: Taking dendritic cells into medicine. Nature 2007, 449:419–426.PubMedCrossRef 13. Hofer S,

Rescigno M, Granucci F, Citterio S, Francolini M, Ricciardi-Castagnoli P: Differential activation of NF-kappa B subunits in dendritic cells in response to Gram-negative bacteria and to lipopolysaccharide. Microbes Infect 2001, 3:259–265.PubMedCrossRef 14. Kaisho T, Tanaka T: Turning NF-kappaB and IRFs on and off in DC. Trends Immunol 2008, 29:329–336.PubMedCrossRef 15. Qing G, Yan P, Xiao G: Hsp90 inhibition Go6983 results in autophagy-mediated proteasome-independent degradation of IkappaB kinase (IKK). Cell Res 2006, 16:895–901.PubMedCrossRef 16. Qing G, Yan P, Qu Z, Liu H, Xiao G: Hsp90 regulates processing of NF-kappa B2 p100 involving protection of NF-kappa B-inducing kinase (NIK) from autophagy-mediated degradation. Cell Res 2007, 17:520–530.PubMedCrossRef 17. Bai L, Xu S, Chen W, Li Z, Wang X, Tang H, Lin Y: Blocking NF-κB and Akt by Hsp90 inhibition sensitizes Smac mimetic compound 3-induced extrinsic apoptosis pathway and results in synergistic cancer cell death. Apoptosis 2011, 16:45–54.PubMedCentralPubMedCrossRef 18.

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>